Skip to main content

Table 2 Outcomes at 12 months in the entire cohort, naïve and non-naïve patients, by ART regimen

From: Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

  All ART naïve ART non-naïve
Efavirenz (n = 647) non Efavirenz (n = 318) Efavirenz (n = 420) non Efavirenz (n = 98) Efavirenz (n = 227) non Efavirenz (n = 220)
Death 84 (13%) 29 (9%) 51 (12%) 10 (10%) 33 (14%) 19 (9%)
LTFU 129 (20%) 50 (16%) 100 (24%) 20 (20%) 29 (13%) 30 (14%)
Undetectable HIV-RNA 220 (34%) 132 (41%) 134 (32%) 35 (36%) 86 (38%) 97 (44%)
Detectable HIV-RNA 67 (11%) 34 (11%) 44 (10%) 8 (8%) 23 (10%) 26 (12%)
Active no VL 147 (23%) 73 (23%) 91 (22%) 25 (25%) 56 (25%) 48 (22%)
p value 0.08 0.78 0.27
  1. Note: p values reflect the comparison of the overall distribution of outcomes for efavirenz- and non-efavirenz containing ART regimens
  2. LTFU lost to follow-up, HIV-RNA Undetectable VL < 400 at 12 months, VL viral load